HomeCompareECGR vs ABBV

ECGR vs ABBV: Dividend Comparison 2026

ECGR yields 250.00% · ABBV yields 3.67%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ECGR wins by $460.86M in total portfolio value
10 years
ECGR
ECGR
● Live price
250.00%
Share price
$0.80
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$460.90M
Annual income
$257,938,329.48
Full ECGR calculator →
ABBV
AbbVie Inc.
● Live price
3.67%
Share price
$168.90
Annual div
$6.20
5Y div CAGR
8.9%
Payout ratio
58%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.9K
Annual income
$1,154.43
Full ABBV calculator →

Portfolio growth — ECGR vs ABBV

📍 ECGR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodECGRABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ECGR + ABBV cover 4 of 12 monthsgood coverage

Jan
ABBV
Feb
Mar
Apr
ABBV
May
Jun
Jul
ABBV
Aug
Sep
Oct
ABBV
Nov
Dec
ECGR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ECGR
Annual income on $10K today (after 15% tax)
$21,250.00/yr
After 10yr DRIP, annual income (after tax)
$219,247,580.06/yr
ABBV
Annual income on $10K today (after 15% tax)
$312.02/yr
After 10yr DRIP, annual income (after tax)
$981.27/yr
At 15% tax rate, ECGR beats the other by $219,246,598.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ECGR + ABBV for your $10,000?

ECGR: 50%ABBV: 50%
100% ABBV50/50100% ECGR
Portfolio after 10yr
$230.47M
Annual income
$128,969,741.96/yr
Blended yield
55.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ECGR
No analyst data
Altman Z
-55.8
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+51.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ECGR buys
0
ABBV buys
0
No recent congressional trades found for ECGR or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricECGRABBV
Forward yield250.00%3.67%
Annual dividend / share$2.00$6.20
Payout ratio50%58%
1-year div growth0%4.7%
5-year div CAGR0%8.9%
Portfolio after 10y$460.90M$39.9K
Annual income after 10y$257,938,329.48$1,154.43
Total dividends collected$439.24M$7.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ECGR vs ABBV ($10,000, DRIP)

YearECGR PortfolioECGR Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$35,700$25,000.00$11,520$399.75+$24.2KECGR
2$121,610$83,411.21$13,261$450.98+$108.3KECGR
3$395,671$265,547.68$15,255$508.41+$380.4KECGR
4$1,230,830$807,462.69$17,536$572.74+$1.21MECGR
5$3,664,475$2,347,486.25$20,145$644.78+$3.64MECGR
6$10,452,787$6,531,799.39$23,126$725.38+$10.43MECGR
7$28,597,316$17,412,833.72$26,532$815.52+$28.57MECGR
8$75,121,556$44,522,427.99$30,420$916.26+$75.09MECGR
9$189,683,639$109,303,574.11$34,855$1,028.80+$189.65MECGR
10$460,899,823$257,938,329.48$39,914$1,154.43+$460.86MECGR

ECGR vs ABBV: Complete Analysis 2026

ECGRStock

Bellatora Inc. manufactures, markets, and distributes electronic vaporizers and eLiquids, and ecigars for tobacco and medicinal cannabis users. The company was formerly known as Oncology Med, Inc. and changed its name to Bellatora Inc. in September 2016. Bellatora Inc. is headquartered in Anaheim, California.

Full ECGR Calculator →

ABBVHealthcare

AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.

Full ABBV Calculator →
📬

Get this ECGR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ECGR vs SCHDECGR vs JEPIECGR vs OECGR vs KOECGR vs MAINECGR vs JNJECGR vs MRKECGR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.